Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

Insmed reported a narrower net loss in the third quarter of 2026 compared with the same period in 2025. The company raised its full-year 2026 ARIKAYCE revenue outlook to $460 million–$470 million and increased overall sales guidance to $1.81 billion–$1.87 billion, citing ongoing commercial performance and its focus on rare diseases.